Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Go back to Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency| Asianada, Inc. (NASDAQ: ASND) | Delayed: 252.66 +0.73 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $251.93 | 52 Week High | $21.79 | |||
| Open | $251.55 | 52 Week Low | $11.92 | |||
| Day High | $256.09 | P/E | N/A | |||
| Day Low | $249.99 | EPS | $-0.07 | |||
| Volume | 308,315 | |||||
